BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE. Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology 2012;55:476-82. [PMID: 21953588 DOI: 10.1002/hep.24710] [Cited by in Crossref: 174] [Cited by in F6Publishing: 180] [Article Influence: 17.4] [Reference Citation Analysis]
Number Citing Articles
1 Liu S, Sun L, Yao L, Zhu H, Diao Y, Wang M, Xing H, Lau WY, Guan M, Pawlik TM, Shen F, Xu M, Tong X, Yang T. Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis. JCM 2022;11:5075. [DOI: 10.3390/jcm11175075] [Reference Citation Analysis]
2 Gao G, Luan X. Diagnostic performance of clusterin in hepatocellular carcinoma: A meta-analysis. Int J Biol Markers. [DOI: 10.1177/03936155221101206] [Reference Citation Analysis]
3 Chen Z, Qi L, Fu H, Ma L. Long non-coding RNA X-inactive specific transcript suppresses the progression of hepatocellular carcinoma through microRNA-221-3p-targeted regulation of O6-methylguanine-DNA methyltransferase. Bioengineered 2022;13:14013-27. [PMID: 35723009 DOI: 10.1080/21655979.2022.2086382] [Reference Citation Analysis]
4 Zhou X, Zhang T, Sun Y, Li C, Ding X, Zhu Y, Li L, Fan Z. Systematic Review and Meta-analysis: Association of Aspirin With Incidence of Hepatocellular Carcinoma. Front Pharmacol 2022;13:764854. [PMID: 35300300 DOI: 10.3389/fphar.2022.764854] [Reference Citation Analysis]
5 Yin J, Wen M, Cheng J, Hu L, Yang L, Chang X, Zhou Z, Li H, Liu Y, Li J. A Patient With Failed Liver Transplantation After the Use of PD-1 Blockade Combined With Lenvaxen. Front Med (Lausanne) 2022;9:712466. [PMID: 35265635 DOI: 10.3389/fmed.2022.712466] [Reference Citation Analysis]
6 Li Y, Zhang J, Zhang K, Chen Y, Wang W, Chen H, Zou Z, Li Y, Dai M. Scutellaria barbata Inhibits Hepatocellular Carcinoma Tumorigenicity by Inducing Ferroptosis of Hepatocellular Carcinoma Cells. Front Oncol 2022;12:693395. [DOI: 10.3389/fonc.2022.693395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Xu W, Cheng Y, Guo Y, Yao W, Qian H. Targeting tumor associated macrophages in hepatocellular carcinoma. Biochemical Pharmacology 2022. [DOI: 10.1016/j.bcp.2022.114990] [Reference Citation Analysis]
8 Tayob N, Lok ASF, Feng Z. A multivariate parametric empirical Bayes screening approach for early detection of hepatocellular carcinoma using multiple longitudinal biomarkers. Stat Med 2022. [PMID: 35199349 DOI: 10.1002/sim.9358] [Reference Citation Analysis]
9 Lu L, Zhuang Z, Fan M, Liu B, Yang Y, Huang J, Da X, Mo J, Li Q, Lu H. Green formulation of Ag nanoparticles by Hibiscus rosa-sinensis: Introducing a navel chemotherapeutic drug for the treatment of liver cancer. Arabian Journal of Chemistry 2022;15:103602. [DOI: 10.1016/j.arabjc.2021.103602] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Han J, Wang B, Liu W, Wang S, Chen R, Chen M, Fu Z. Declining disease burden of HCC in the United States, 1992-2017: A population-based analysis. Hepatology 2022. [PMID: 35073427 DOI: 10.1002/hep.32355] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
11 Martin D, Maeder Y, Kobayashi K, Schneider M, Koerfer J, Melloul E, Halkic N, Hübner M, Demartines N, Becce F, Uldry E. Association between CT-Based Preoperative Sarcopenia and Outcomes in Patients That Underwent Liver Resections. Cancers (Basel) 2022;14:261. [PMID: 35008425 DOI: 10.3390/cancers14010261] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Fan Z, Wu M, Tang Z, He A, Liu F, Liang W, Wang Z, Yang D. Predictive Value of Platelet-Related Measures in Patients with Hepatocellular Carcinoma. Technol Cancer Res Treat 2022;21:15330338211064414. [PMID: 35225081 DOI: 10.1177/15330338211064414] [Reference Citation Analysis]
13 Forjaz G, Howlader N, Scoppa S, Johnson CJ, Mariotto AB. Impact of including second and later cancers in cause-specific survival estimates using population-based registry data. Cancer 2021. [PMID: 34623641 DOI: 10.1002/cncr.33940] [Reference Citation Analysis]
14 Shi T, Morishita A, Kobara H, Masaki T. The Role of Long Non-Coding RNA and microRNA Networks in Hepatocellular Carcinoma and Its Tumor Microenvironment. Int J Mol Sci 2021;22:10630. [PMID: 34638971 DOI: 10.3390/ijms221910630] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Liao R, Zhang D, Li X, Ma J, Yu J, Yang C, Xiong H, Zhou B, Huang X, Tang Z. A Preliminary Study on the Diagnostic Efficacy of Proton Magnetic Resonance Spectroscopy at 3.0T in Rabbit With VX2 Liver Tumor. Technol Cancer Res Treat 2021;20:15330338211036852. [PMID: 34372732 DOI: 10.1177/15330338211036852] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Zhu S, Cao S, Yang W, Che J, Li D, Pei R, Ding Y. The Maturation of Tumor Suppressor miR-497 in Hepatocellular Carcinoma is Inhibited by Oncogenic circRNA SCARB1. Cancer Manag Res 2021;13:5751-9. [PMID: 34305409 DOI: 10.2147/CMAR.S304125] [Reference Citation Analysis]
17 Zeng C, Tang Y, Jiang Y, Zuo Z, Tao H. Long noncoding RNAs as biomarkers for the diagnosis of hepatocellular carcinoma: A meta-analysis. Pathol Res Pract 2021;224:153546. [PMID: 34332221 DOI: 10.1016/j.prp.2021.153546] [Reference Citation Analysis]
18 Schwabe RF, Greten TF. Gut microbiome in HCC - Mechanisms, diagnosis and therapy. J Hepatol. 2020;72:230-238. [PMID: 31954488 DOI: 10.1016/j.jhep.2019.08.016] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 51.0] [Reference Citation Analysis]
19 Wong RJ, Ahmed A; Hepatocellular Carcinoma Research Committee of the Chronic Liver Disease Foundation. Understanding Gaps in the Hepatocellular Carcinoma Cascade of Care: Opportunities to Improve Hepatocellular Carcinoma Outcomes.J Clin Gastroenterol. 2020;54:850-856. [PMID: 33030855 DOI: 10.1097/MCG.0000000000001422] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
20 Dian MJ, Li J, Zhang XL, Li ZJ, Zhou Y, Zhou W, Zhong QL, Pang WQ, Lin XL, Liu T, Liu YA, Li YL, Han LX, Zhao WT, Jia JS, Xiao SJ, Xiao D, Xia JW, Hao WC. MST4 negatively regulates the EMT, invasion and metastasis of HCC cells by inactivating PI3K/AKT/Snail1 axis. J Cancer 2021;12:4463-77. [PMID: 34149910 DOI: 10.7150/jca.60008] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Wen N, Liu F, Zhang H, Lu J, Li B, Cheng N. Laparoscopic liver resection for hepatocellular carcinoma presents less respiratory complications compared with open procedure: A propensity score analysis in the elderly. Eur J Surg Oncol 2021:S0748-7983(21)00463-7. [PMID: 34059378 DOI: 10.1016/j.ejso.2021.04.032] [Reference Citation Analysis]
22 Wen L, Weng S, Yan C, Ye R, Zhu Y, Zhou L, Gao L, Li Y. A Radiomics Nomogram for Preoperative Prediction of Early Recurrence of Small Hepatocellular Carcinoma After Surgical Resection or Radiofrequency Ablation. Front Oncol 2021;11:657039. [PMID: 34026632 DOI: 10.3389/fonc.2021.657039] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
23 Hu S, Liu J, Feng S, Wang Y, Liu H. LncRNA SUMO1P3 acts as a prognostic biomarker and promotes hepatocellular carcinoma growth and metastasis. Aging (Albany NY) 2021;13:12479-92. [PMID: 33902004 DOI: 10.18632/aging.202921] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
24 Flores YN, Datta GD, Yang L, Corona E, Devineni D, Glenn BA, Bastani R, May FP. Disparities in Hepatocellular Carcinoma Incidence, Stage, and Survival: A Large Population-Based Study. Cancer Epidemiol Biomarkers Prev 2021;30:1193-9. [PMID: 33737301 DOI: 10.1158/1055-9965.EPI-20-1088] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
25 Zhu W, Li J, Zhang Y, Zhu Z, Liu H, Lin Y, Hu A, Zhou J, Ren H, Shi X. Inhibition of HMGB1 Suppresses Hepatocellular Carcinoma Progression via HIPK2-Mediated Autophagic Degradation of ZEB1. Front Oncol 2021;11:599124. [PMID: 33747917 DOI: 10.3389/fonc.2021.599124] [Reference Citation Analysis]
26 Yang Y, Zhang Y, Miao L, Liao W, Liao W. LncRNA PPP1R14B-AS1 Promotes Tumor Cell Proliferation and Migration via the Enhancement of Mitochondrial Respiration. Front Genet 2020;11:557614. [PMID: 33262783 DOI: 10.3389/fgene.2020.557614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Pomenti S, Gandle C, Abu Sbeih H, Phipps M, Livanos A, Guo A, Yeh J, Burney H, Liu H, Dakhoul L, Kettler C, Gawrieh S, deLemos A, Scanga A, Chalasani N, Miller E, Wattacheril J. Hepatocellular Carcinoma in Hispanic Patients: Trends and Outcomes in a Large United States Cohort. Hepatol Commun 2020;4:1708-16. [PMID: 33163839 DOI: 10.1002/hep4.1575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Rich NE, John BV, Parikh ND, Rowe I, Mehta N, Khatri G, Thomas SM, Anis M, Mendiratta-Lala M, Hernandez C, Odewole M, Sundaram LT, Konjeti VR, Shetty S, Shah T, Zhu H, Yopp AC, Hoshida Y, Yao FY, Marrero JA, Singal AG. Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. Hepatology 2020;72:1654-65. [PMID: 32017165 DOI: 10.1002/hep.31159] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 28.5] [Reference Citation Analysis]
29 Cong M, Ou X, Huang J, Long J, Li T, Liu X, Wang Y, Wu X, Zhou J, Sun Y, Shang Q, Chen G, Ma H, Xie W, Piao H, Yang Y, Gao Z, Xu X, Tan Z, Chen C, Zeng N, Wu S, Kong Y, Liu T, Wang P, You H, Jia J, Zhuang H. A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus. OMICS 2020;24:415-23. [PMID: 32522092 DOI: 10.1089/omi.2020.0055] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
30 Yoon JS, Lee HA, Park JY, Kim BH, Lee IJ, Chon YE, Hong SK, Lee DH, Kong H, Won Y, Kim E, Lee J. Hepatocellular Carcinoma in Korea Between 2008 and 2011: an Analysis of Korean Nationwide Cancer Registry. J Liver Cancer 2020;20:41-52. [DOI: 10.17998/jlc.20.1.41] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
31 Fang P, Du L, Cai D. Evaluation of plasma D-dimer for the diagnosis in Chinese patients with hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2020;99:e19461. [PMID: 32195943 DOI: 10.1097/MD.0000000000019461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Wan S, Nie Y, Zhu X. Development of a prognostic scoring model for predicting the survival of elderly patients with hepatocellular carcinoma. PeerJ 2020;8:e8497. [PMID: 32117619 DOI: 10.7717/peerj.8497] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
33 Wong LL. Surveillance of hepatocellular cancer-why can't we do better? Hepatobiliary Surg Nutr 2019;8:662-3. [PMID: 31930002 DOI: 10.21037/hbsn.2019.07.20] [Reference Citation Analysis]
34 Ladhani S, Ohri A, Wong RJ. Disparities in Hepatocellular Carcinoma Surveillance: Dissecting the Roles of Patient, Provider, and Health System Factors. Journal of Clinical Gastroenterology 2020;54:218-26. [DOI: 10.1097/mcg.0000000000001313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
35 Li Y, Xu W, Chen P, Liao M, Qin W, Liao W, Huang Z. Correlation Analysis Between Preoperative Serum Iron Level and Prognosis as Well as Recurrence of HCC After Radical Resection. Cancer Manag Res 2020;12:31-41. [PMID: 32021420 DOI: 10.2147/CMAR.S227418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Lu F, Zhou Q, Liu L, Zeng G, Ci W, Liu W, Zhang G, Zhang Z, Wang P, Zhang A, Gao Y, Yu L, He Q, Chen L. A tumor suppressor enhancing module orchestrated by GATA4 denotes a therapeutic opportunity for GATA4 deficient HCC patients. Theranostics 2020;10:484-97. [PMID: 31903133 DOI: 10.7150/thno.38060] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
37 Kudo M. Management of Hepatocellular Carcinoma in Japan: Current Trends. Liver Cancer 2020;9:1-5. [PMID: 32071904 DOI: 10.1159/000505370] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
38 Zheng W, Li Q, Zou XB, Wang JW, Han F, Li F, Huang LS, Li AH, Zhou JH. Evaluation of Contrast-enhanced US LI-RADS version 2017: Application on 2020 Liver Nodules in Patients with Hepatitis B Infection. Radiology. 2020;294:299-307. [PMID: 31769742 DOI: 10.1148/radiol.2019190878] [Cited by in Crossref: 18] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
39 Qiu C, Liu Y, Mei Y, Zou M, Zhao Z, Ye M, Wu X. Ubiquitin-specific protease 4 promotes metastasis of hepatocellular carcinoma by increasing TGF-β signaling-induced epithelial-mesenchymal transition. Aging (Albany NY) 2018;10:2783-99. [PMID: 30335615 DOI: 10.18632/aging.101587] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
40 Sempokuya T, Wong LL. Ten-year survival and recurrence of hepatocellular cancer. Hepatoma Res 2019;5:38. [PMID: 31701016 DOI: 10.20517/2394-5079.2019.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
41 Sun Z, Yan B. Multiple roles and regulatory mechanisms of the transcription factor GATA6 in human cancers. Clin Genet 2020;97:64-72. [PMID: 31437305 DOI: 10.1111/cge.13630] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
42 Yang MY, Hung TW, Wang CJ, Tseng TH. Inhibitory Effect of Nelumbo nucifera Leaf Extract on 2-Acetylaminofluorene-induced Hepatocarcinogenesis Through Enhancing Antioxidative Potential and Alleviating Inflammation in Rats. Antioxidants (Basel) 2019;8:E329. [PMID: 31443426 DOI: 10.3390/antiox8090329] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
43 Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019;157:1253-1263.e2. [PMID: 31374215 DOI: 10.1053/j.gastro.2019.07.040] [Cited by in Crossref: 53] [Cited by in F6Publishing: 75] [Article Influence: 17.7] [Reference Citation Analysis]
44 Chen X, Gao J, Wang T, Jiang X, Chen J, Liang X, Wu J. Hepatocarcinoma Discrimination by Ratiometric Lipid Profiles Using Tip-Contact Sampling/Ionization Mass Spectrometry. Anal Chem 2019;91:10376-80. [DOI: 10.1021/acs.analchem.9b02623] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
45 Wang J, Ha J, Lopez A, Bhuket T, Liu B, Wong RJ. Medicaid and Uninsured Hepatocellular Carcinoma Patients Have More Advanced Tumor Stage and Are Less Likely to Receive Treatment. J Clin Gastroenterol 2018;52:437-43. [PMID: 28723861 DOI: 10.1097/MCG.0000000000000859] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
46 Forjaz de Lacerda G, Howlader N, Mariotto AB. Differences in Cancer Survival with Relative versus Cause-Specific Approaches: An Update Using More Accurate Life Tables. Cancer Epidemiol Biomarkers Prev 2019;28:1544-51. [PMID: 31221717 DOI: 10.1158/1055-9965.EPI-19-0125] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
47 Zhang M, Hu J, Li H, Zhang S, Hu W, Wu L, Han B. High TNF-α and/or p38MAPK expression predicts a favourable prognosis in patients with T1N0M0 hepatocellular carcinoma: An immunohistochemical study. Oncol Lett 2019;17:4948-56. [PMID: 31186704 DOI: 10.3892/ol.2019.10193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
48 Di Sandro S, Bagnardi V, Cucchetti A, Lauterio A, De Carlis R, Benuzzi L, Danieli M, Botta F, Centonze L, Najjar M, De Carlis L. From a Philosophical Framework to a Valid Prognostic Staging System of the New "Comprehensive Assessment" for Transplantable Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E741. [PMID: 31142035 DOI: 10.3390/cancers11060741] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
49 Salum GM, Dawood RM, Abd El-Meguid M, Ibrahim NE, Abdel Aziz AO, El Awady MK. Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients. Genes Dis 2020;7:392-400. [PMID: 32884993 DOI: 10.1016/j.gendis.2019.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
50 Kuftinec GN, Levy R, Kieffer DA, Medici V. Hepatocellular Carcinoma and Associated Clinical Features in Latino and Caucasian Patients from a Single Center. Ann Hepatol 2019;18:177-86. [PMID: 31113588 DOI: 10.5604/01.3001.0012.7910] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
51 Yu S, Zhou X, Xiang H, Wang S, Cui Z, Zhou J. Resveratrol Reduced Liver Damage After Liver Resection in a Rat Model by Upregulating Sirtuin 1 (SIRT1) and Inhibiting the Acetylation of High Mobility Group Box 1 (HMGB1). Med Sci Monit 2019;25:3212-20. [PMID: 31041919 DOI: 10.12659/MSM.913937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
52 Gans JH, Lipman J, Golowa Y, Kinkhabwala M, Kaubisch A. Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in? Seminars in Nuclear Medicine 2019;49:170-81. [DOI: 10.1053/j.semnuclmed.2019.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
53 Wu J, Sun C, Li E, Wang J, He X, Yuan R, Yi C, Liao W, Wu L. Non-functional pancreatic neuroendocrine tumours: emerging trends in incidence and mortality. BMC Cancer 2019;19:334. [PMID: 30961556 DOI: 10.1186/s12885-019-5543-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
54 Zhao R, Li L, Yang J, Niu Q, Wang H, Qin X, Zhu N, Shi A. Overexpression of Pyruvate Kinase M2 in Tumor Tissues Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. Pathol Oncol Res 2020;26:853-60. [PMID: 30852741 DOI: 10.1007/s12253-019-00630-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
55 Tripathi A, Shrinet K, Kumar A. HMGB1 protein as a novel target for cancer. Toxicol Rep 2019;6:253-61. [PMID: 30911468 DOI: 10.1016/j.toxrep.2019.03.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
56 Qin Y, Lu H. In vitro evaluation of anti-hepatoma activity of brevilin A: involvement of Stat3/Snail and Wnt/β-catenin pathways. RSC Adv 2019;9:4390-6. [PMID: 35547606 DOI: 10.1039/c8ra08574a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
57 Yang X, Li S, Wang H, Chen W, Mou X, Wang S. Expression of coxsackie and adenovirus receptor is correlated with inferior prognosis in liver cancer patients. Oncol Lett 2019;17:2485-90. [PMID: 30719117 DOI: 10.3892/ol.2018.9868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
58 Yao J, Zhang X, Li J, Zhao D, Gao B, Zhou H, Gao S, Zhang L. Silencing TRIP13 inhibits cell growth and metastasis of hepatocellular carcinoma by activating of TGF-β1/smad3. Cancer Cell Int 2018;18:208. [PMID: 30564064 DOI: 10.1186/s12935-018-0704-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
59 Wang Z, Shi Z, Zhang L, Zhang H, Zhang Y. Profilin 1, negatively regulated by microRNA-19a-3p, serves as a tumor suppressor in human hepatocellular carcinoma. Pathol Res Pract 2019;215:499-505. [PMID: 30638858 DOI: 10.1016/j.prp.2018.12.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
60 Carville KS, MacLachlan JH, Thursfield V, Cowie BC. Hepatocellular carcinoma over three decades in Victoria, Australia: epidemiology, diagnosis and trends, 1984-2013. Intern Med J 2018;48:835-44. [PMID: 29604152 DOI: 10.1111/imj.13823] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
61 O’Rourke JM, Sagar VM, Shah T, Shetty S. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer. World J Gastroenterol 2018; 24(39): 4436-4447 [PMID: 30357021 DOI: 10.3748/wjg.v24.i39.4436] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 62] [Article Influence: 18.3] [Reference Citation Analysis]
62 Di Sandro S, Bagnardi V, Najjar M, Buscemi V, Lauterio A, De Carlis R, Danieli M, Pinotti E, Benuzzi L, De Carlis L. Minor laparoscopic liver resection for Hepatocellular Carcinoma is safer than minor open resection, especially for less compensated cirrhotic patients: Propensity score analysis. Surg Oncol. 2018;27:722-729. [PMID: 30449499 DOI: 10.1016/j.suronc.2018.10.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
63 Wang YD, Sun XJ, Yang WJ, Li J, Yin JJ. Magnolol exerts anticancer activity in hepatocellular carcinoma cells through regulating endoplasmic reticulum stress-mediated apoptotic signaling. Onco Targets Ther 2018;11:5219-26. [PMID: 30214227 DOI: 10.2147/OTT.S168887] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
64 Orcutt ST, Anaya DA. Liver Resection and Surgical Strategies for Management of Primary Liver Cancer. Cancer Control 2018;25:1073274817744621. [PMID: 29327594 DOI: 10.1177/1073274817744621] [Cited by in Crossref: 49] [Cited by in F6Publishing: 85] [Article Influence: 12.3] [Reference Citation Analysis]
65 Yang B, Liu JB, So SK, Han SS, Wang SS, Hertz A, Shariff-Marco S, Lin Gomez S, Rosenberg PS, Nguyen MH, Hsing AW. Disparities in hepatocellular carcinoma incidence by race/ethnicity and geographic area in California: Implications for prevention. Cancer 2018;124:3551-9. [PMID: 30113700 DOI: 10.1002/cncr.31598] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
66 Gelu-Simeon M, Lewin M, Ostos M, Bayan T, Beso Delgado M, Teicher E, Layese R, Roudot-Thoraval F, Fontaine H, Sobesky R, Salmon-Céron D, Samuel D, Seror O, Nahon P, Meyer L, Duclos-Vallée JC; ANRS HC EP 25 Prethevic, ANRS CO13 HepaVih and ANRS CO12 CirVir Study Groups. Prognostic factors of survival in HIV/HCV co-infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort. Liver Int 2019;39:136-46. [PMID: 29947467 DOI: 10.1111/liv.13921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
67 Sun YW, Qiu HC, Ou MC, Chen RL, Liang G. Saponins isolated from Schizocapsa plantaginea inhibit human hepatocellular carcinoma cell growth in vivo and in vitro via mitogen-activated protein kinase signaling. Chin J Nat Med 2018;16:29-40. [PMID: 29425588 DOI: 10.1016/S1875-5364(18)30027-X] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
68 Yang JD, Mannalithara A, Piscitello AJ, Kisiel JB, Gores GJ, Roberts LR, Kim WR. Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. Hepatology 2018;68:78-88. [PMID: 29023828 DOI: 10.1002/hep.29594] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
69 Jiang T, Huang Z, Zhang S, Zou W, Xiang L, Wu X, Shen Y, Liu W, Zeng Z, Zhao A, Zhou S, Zeng Q. miR‑23b inhibits proliferation of SMMC‑7721 cells by directly targeting IL‑11. Mol Med Rep 2018;18:1591-9. [PMID: 29901200 DOI: 10.3892/mmr.2018.9151] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 Zhang YF, Zeng XL, Lu HW, Ji H, Lu L, Liu PD, Hong RF, Li YM. Association between KIF1B (rs17401966) polymorphism and hepatocellular carcinoma susceptibility: a meta-analysis. Onco Targets Ther 2018;11:3225-35. [PMID: 29881295 DOI: 10.2147/OTT.S162205] [Reference Citation Analysis]
71 Sheppard-Law S, Zablotska-Manos I, Kermeen M, Holdaway S, Lee A, George J, Zekry A, Maher L. Utilisation of hepatocellular carcinoma screening in Australians at risk of hepatitis B virus-related carcinoma and prescribed anti-viral therapy. J Clin Nurs 2018;27:2673-83. [PMID: 29603817 DOI: 10.1111/jocn.14367] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
72 Ye X, Wang X, Shang L, Zhu G, Su H, Han C, Qin W, Li G, Peng T. Genetic variants of ALDH2-rs671 and CYP2E1-rs2031920 contributed to risk of hepatocellular carcinoma susceptibility in a Chinese population. Cancer Manag Res 2018;10:1037-50. [PMID: 29765251 DOI: 10.2147/CMAR.S162105] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
73 Huang G, Jiang H, Lin Y, Wu Y, Cai W, Shi B, Luo Y, Jian Z, Zhou X. lncAKHE enhances cell growth and migration in hepatocellular carcinoma via activation of NOTCH2 signaling. Cell Death Dis 2018;9:487. [PMID: 29706630 DOI: 10.1038/s41419-018-0554-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
74 Kim NG, Nguyen PP, Dang H, Kumari R, Garcia G, Esquivel CO, Nguyen MH. Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015: Long-Term Survival in Patients With HCC. Cancer 2018;124:2588-98. [DOI: 10.1002/cncr.31373] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
75 Zhu Q, Luo Z, Lu G, Gui F, Wu J, Li F, Ni Y. LncRNA FABP5P3/miR-589-5p/ZMYND19 axis contributes to hepatocellular carcinoma cell proliferation, migration and invasion. Biochemical and Biophysical Research Communications 2018;498:551-8. [DOI: 10.1016/j.bbrc.2018.03.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
76 Ma XL, Zhu J, Wu J, Tian L, Gao YY, Zhang CY, Zhou Y, Dai Q, Wang BL, Pan BS, Zhou J, Fan J, Yang XR, Guo W. Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma. Oncol Lett 2018;15:8396-404. [PMID: 29805574 DOI: 10.3892/ol.2018.8375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
77 Zhang K, Zhao Z, Yu J, Chen W, Xu Q, Chen L. LncRNA FLVCR1‐AS1 acts as miR‐513c sponge to modulate cancer cell proliferation, migration, and invasion in hepatocellular carcinoma. J Cell Biochem 2018;119:6045-56. [DOI: 10.1002/jcb.26802] [Cited by in Crossref: 28] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
78 Di Sandro S, Sposito C, Lauterio A, Najjar M, Droz Dit Busset M, Buscemi V, Flores Reyes M, De Carlis R, Mazzaferro V, De Carlis L. Proposal of Prognostic Survival Models before and after Liver Resection for Hepatocellular Carcinoma in Potentially Transplantable Patients. J Am Coll Surg 2018;226:1147-59. [PMID: 29574178 DOI: 10.1016/j.jamcollsurg.2018.03.025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
79 Hwang IC, Chang J, Kim K, Park SM. Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults. Sci Rep 2018;8:4968. [PMID: 29563592 DOI: 10.1038/s41598-018-23343-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
80 Jiang X, Wu J, Zhang Y, Wang S, Yu X, Li R, Huang X. MiR-613 functions as tumor suppressor in hepatocellular carcinoma by targeting YWHAZ. Gene 2018;659:168-74. [PMID: 29551505 DOI: 10.1016/j.gene.2018.03.036] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
81 Wang L, Tong D, Guo Q, Wang X, Wu F, Li Q, Yang J, Zhao L, Qin Y, Liu Y, Huang C. HOXD3 targeted by miR-203a suppresses cell metastasis and angiogenesis through VEGFR in human hepatocellular carcinoma cells. Sci Rep 2018;8:2431. [PMID: 29402992 DOI: 10.1038/s41598-018-20859-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
82 Dong D, Zou Y, Zhang P, Wu Z. Systematic analyses and comprehensive field synopsis of genetic association studies in hepatocellular carcinoma. Oncotarget 2016;7:45757-63. [PMID: 27304192 DOI: 10.18632/oncotarget.9937] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
83 Dai XM, Yang SL, Zheng XM, Chen GG, Chen J, Zhang T. CD133 expression and α-fetoprotein levels define novel prognostic subtypes of HBV-associated hepatocellular carcinoma: A long-term follow-up analysis. Oncol Lett 2018;15:2985-91. [PMID: 29435028 DOI: 10.3892/ol.2017.7704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
84 Kudo M. Management of Hepatocellular Carcinoma in Japan as a World-Leading Model. Liver Cancer 2018;7:134-47. [PMID: 29888204 DOI: 10.1159/000484619] [Cited by in Crossref: 20] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
85 Sengupta S, Parikh ND. Biomarker development for hepatocellular carcinoma early detection: Current and future perspectives. Hepat Oncol. 2017;4:111-122. [PMID: 30191058 DOI: 10.2217/hep-2017-0019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
86 Hong YM, Cho M, Yoon KT, Chu CW, Yang KH, Park YM, Rhu JH. Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma. Tumour Biol. 2017;39:1010428317720863. [PMID: 29034775 DOI: 10.1177/1010428317720863] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
87 Yu H, Jia R, Zhao L, Song S, Gu J, Zhang H. LDB2 inhibits proliferation and migration in liver cancer cells by abrogating HEY1 expression. Oncotarget 2017;8:94440-9. [PMID: 29212240 DOI: 10.18632/oncotarget.21772] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
88 Abdel-rahman O, Helbling D, Schöb O, Eltobgy M, Mohamed H, Schmidt J, giryes A, Mehrabi A, Iype S, John H, Tekbas A, Zidan A, Oweira H. Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma: An updated systematic review of 81 epidemiological studies. J Evid Based Med 2017;10:245-54. [DOI: 10.1111/jebm.12270] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
89 Lee PC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lee MH, Hou MC, Lee FY, Lin HC, Huang YH. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma. Liver Int. 2018;38:321-330. [PMID: 28736952 DOI: 10.1111/liv.13527] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
90 Xu YC, Liang CJ, Zhang DX, Li GQ, Gao X, Fu JZ, Xia F, Ji JJ, Zhang LJ, Li GM, Wu JX. LncSHRG promotes hepatocellular carcinoma progression by activating HES6. Oncotarget 2017;8:70630-41. [PMID: 29050307 DOI: 10.18632/oncotarget.19906] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
91 Kalyan A, Kulik L. Multidisciplinary Care in Hepatocellular Carcinoma: Where Do We Go From Here? Gastroenterology 2017;152:1823-5. [PMID: 28461194 DOI: 10.1053/j.gastro.2017.04.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
92 Mohsen W, Rodov M, Prakoso E, Charlton B, Bowen DG, Koorey DJ, Shackel NA, McCaughan GW, Strasser SI. Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma. World J Gastroenterol 2017; 23(15): 2763-2770 [PMID: 28487614 DOI: 10.3748/wjg.v23.i15.2763] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
93 Xue F, Yin J, Xu L, Wang B. MicroRNA-143 inhibits tumorigenesis in hepatocellular carcinoma by downregulating GATA6. Exp Ther Med. 2017;13:2667-2674. [PMID: 28587328 DOI: 10.3892/etm.2017.4348] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
94 Venepalli NK, Modayil MV, Berg SA, Nair TD, Parepally M, Rajaram P, Gaba RC, Bui JT, Huang Y, Cotler SJ. Features of hepatocellular carcinoma in Hispanics differ from African Americans and non-Hispanic Whites. World J Hepatol 2017; 9(7): 391-400 [PMID: 28321275 DOI: 10.4254/wjh.v9.i7.391] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
95 Serper M, Taddei TH, Mehta R, D'Addeo K, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Goldberg DS, Valderrama A, Kaplan DE; VOCAL Study Group. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. Gastroenterology. 2017;152:1954-1964. [PMID: 28283421 DOI: 10.1053/j.gastro.2017.02.040] [Cited by in Crossref: 94] [Cited by in F6Publishing: 113] [Article Influence: 18.8] [Reference Citation Analysis]
96 Pan Y, Qin T, Yin S, Zhang X, Gao X, Mu L. Long non-coding RNA UC001kfo promotes hepatocellular carcinoma proliferation and metastasis by targeting α-SMA. Biomedicine & Pharmacotherapy 2017;87:669-77. [DOI: 10.1016/j.biopha.2017.01.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
97 Elsayes KM, Kielar AZ, Agrons MM, Szklaruk J, Tang A, Bashir MR, Mitchell DG, Do RK, Fowler KJ, Chernyak V, Sirlin CB. Liver Imaging Reporting and Data System: an expert consensus statement.J Hepatocell Carcinoma. 2017;4:29-39. [PMID: 28255543 DOI: 10.2147/JHC.S125396] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
98 Hsieh WY, Chen PH, Lin IY, Su CW, Chao Y, Huo TI, Huang YH, Hou MC, Lin HC, Wu JC. The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma. Sci Rep 2017;7:42577. [PMID: 28209963 DOI: 10.1038/srep42577] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
99 Peng J, Li JJ, Li J, Li HW, Xu GP, Jia RR, Zhang XN, Zhao Y. Could ADC values be a promising diagnostic criterion for differentiating malignant and benign hepatic lesions in Asian populations: A meta-analysis. Medicine (Baltimore) 2016;95:e5470. [PMID: 27902599 DOI: 10.1097/MD.0000000000005470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
100 Li SQ, Pan XF, Kashaf MS, Xue QP, Luo HJ, Wang YY, Wen Y, Yang ChX. Five-Year Survival is Not a Useful Measure for Cancer Control in the Population: an Analysis Based on UK Data. Asian Pac J Cancer Prev 2017;18:571-6. [PMID: 28345847 DOI: 10.22034/APJCP.2017.18.2.571] [Reference Citation Analysis]
101 Ladd LM, Tirkes T, Tann M, Agarwal DM, Johnson MS, Tahir B, Sandrasegaran K. Comparison of hepatic MDCT, MRI, and DSA to explant pathology for the detection and treatment planning of hepatocellular carcinoma. Clin Mol Hepatol 2016;22:450-7. [PMID: 27987537 DOI: 10.3350/cmh.2016.0036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
102 Li DJ, Park Y, Vachharajani N, Aung WY, Garonzik-Wang J, Chapman WC. Physician-Patient Communication is Associated With Hepatocellular Carcinoma Screening in Chronic Liver Disease Patients. J Clin Gastroenterol 2017;51:454-60. [PMID: 27918312 DOI: 10.1097/MCG.0000000000000747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
103 Fan F, Wu H, Liu Z, Hou X, Chen W, Wang A, Lu Y. Nuclear PKM2 expression, an independent risk factor for ER after curative resection of hepatocellular carcinoma. Biomedicine & Pharmacotherapy 2016;84:1858-64. [DOI: 10.1016/j.biopha.2016.10.108] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
104 Yang B, Shebl FM, Sternberg LR, Warner AC, Kleiner DE, Edelman DC, Gomez A, Dagnall CL, Hicks BD, Altekruse SF, Hernandez BY, Lynch CF, Meltzer PS, McGlynn KA. Telomere Length and Survival of Patients with Hepatocellular Carcinoma in the United States. PLoS One 2016;11:e0166828. [PMID: 27880792 DOI: 10.1371/journal.pone.0166828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
105 Sun Y, Qiu H, Ou M, Chen R, Liang G. Taccaoside induces apoptosis in hepatocellular carcinoma cell lines. J Int Med Res 2016;44:1395-402. [PMID: 27856932 DOI: 10.1177/0300060516672368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
106 Lan QY, Zhang YJ, Liao GC, Zhou RF, Zhou ZG, Chen YM, Zhu HL. The Association between Dietary Vitamin A and Carotenes and the Risk of Primary Liver Cancer: A Case-Control Study. Nutrients 2016;8:E624. [PMID: 27727160 DOI: 10.3390/nu8100624] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
107 Wang J, Shi Y, Bai Z, Li Y, Qiu L, Johnson G, Zhang F, Yang X. Radiofrequency hyperthermia-enhanced herpes simplex virus-thymidine kinase/ganciclovir direct intratumoral gene therapy of hepatocellular carcinoma. Int J Hyperthermia 2017;33:170-7. [PMID: 27569361 DOI: 10.1080/02656736.2016.1229045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
108 Ke S, Gao J, Kong J, Ding XM, Niu HG, Xin ZH, Ning CM, Guo SG, Li XL, Zhang L, Dong YH, Sun WB. Repeated Radiofrequency Ablation Combined With Ablated Lesion Elimination and Transarterial Chemoembolization Improves the Outcome of Solitary Huge Hepatocellular Carcinomas 10 m or Larger. Medicine (Baltimore) 2016;95:e3393. [PMID: 27100425 DOI: 10.1097/MD.0000000000003393] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
109 Burke LM, Sofue K, Alagiyawanna M, Nilmini V, Muir AJ, Choudhury KR, Semelka RC, Bashir MR. Natural history of liver imaging reporting and data system category 4 nodules in MRI. Abdom Radiol (NY) 2016;41:1758-66. [PMID: 27145771 DOI: 10.1007/s00261-016-0762-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
110 Lee PC, Yeh CM, Hu YW, Chen CC, Liu CJ, Su CW, Huo TI, Huang YH, Chao Y, Chen TJ, Lin HC, Wu JC. Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. Ann Surg Oncol 2016;23:874-83. [PMID: 27541812 DOI: 10.1245/s10434-016-5520-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
111 Ladenheim MR, Kim NG, Nguyen P, Le A, Stefanick ML, Garcia G, Nguyen MH. Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study. BMJ Open Gastroenterol 2016;3:e000107. [PMID: 27493763 DOI: 10.1136/bmjgast-2016-000107] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
112 Qi X, Lam SS, Liu D, Kim DY, Ma L, Alleruzzo L, Chen W, Hode T, Henry CJ, Kaifi J, Kimchi ET, Li G, Staveley-O'Carroll KF. Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer. J Clin Cell Immunol 2016;7:438. [PMID: 27656328 DOI: 10.4172/2155-9899.1000438] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
113 Mokdad AA, Zhu H, Marrero JA, Mansour JC, Singal AG, Yopp AC. Hospital Volume and Survival After Hepatocellular Carcinoma Diagnosis. American Journal of Gastroenterology 2016;111:967-75. [DOI: 10.1038/ajg.2016.181] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
114 Kudo M, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M; Liver Cancer Study Group of Japan. Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan. Liver Cancer 2016;5:190-7. [PMID: 27493894 DOI: 10.1159/000367775] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 9.5] [Reference Citation Analysis]
115 Li G, Staveley-O'Carroll KF, Kimchi ET. Potential of Radiofrequency Ablation in Combination with Immunotherapy in the Treatment of Hepatocellular Carcinoma. J Clin Trials. 2016;6. [PMID: 28042519 DOI: 10.4172/2167-0870.1000257] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
116 Liu Z, Hu Y, Liang H, Sun Z, Feng S, Deng H. Silencing PRDX3 Inhibits Growth and Promotes Invasion and Extracellular Matrix Degradation in Hepatocellular Carcinoma Cells. J Proteome Res 2016;15:1506-14. [PMID: 26983019 DOI: 10.1021/acs.jproteome.5b01125] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
117 Yang S, Liu L, Yang S, Liu L, Ren J, Fang X, Chen GG, Lai PBS. Preoperative serum α-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma. British Journal of Surgery 2016;103:716-24. [DOI: 10.1002/bjs.10093] [Cited by in Crossref: 34] [Cited by in F6Publishing: 57] [Article Influence: 5.7] [Reference Citation Analysis]
118 Chia J, Goh G, Bard F. Short O-GalNAc glycans: regulation and role in tumor development and clinical perspectives. Biochim Biophys Acta 2016;1860:1623-39. [PMID: 26968459 DOI: 10.1016/j.bbagen.2016.03.008] [Cited by in Crossref: 55] [Cited by in F6Publishing: 62] [Article Influence: 9.2] [Reference Citation Analysis]
119 Prenner S, Kulik L. HCC: Where Does HCV Therapy Play a Role? Curr Hepatology Rep 2016;15:17-25. [DOI: 10.1007/s11901-016-0292-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
120 Kao WY, Chao Y, Chang CC, Li CP, Su CW, Huo TI, Huang YH, Chang YJ, Lin HC, Wu JC. Prognosis of Early-Stage Hepatocellular Carcinoma: The Clinical Implications of Substages of Barcelona Clinic Liver Cancer System Based on a Cohort of 1265 Patients. Medicine (Baltimore). 2015;94:e1929. [PMID: 26512620 DOI: 10.1097/md.0000000000001929] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
121 Patel N, Yopp AC, Singal AG. Diagnostic delays are common among patients with hepatocellular carcinoma. J Natl Compr Canc Netw 2015;13:543-9. [PMID: 25964640 DOI: 10.6004/jnccn.2015.0074] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
122 Chen VL, Le AK, Kim NG, Kim LH, Nguyen NH, Nguyen PP, Zhao C, Nguyen MH. Effects of Cirrhosis on Short-term and Long-term Survival of Patients With Hepatitis B-related Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2016;14:887-895.e1. [PMID: 26820401 DOI: 10.1016/j.cgh.2015.12.044] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
123 Li M, Zhao H, Bi X, Li Z, Huang Z, Han Y, Zhou J, Zhao J, Zhang Y, Wei W, Zhao D, Cai J. Total tumor volume predicts survival following liver resection in patients with hepatocellular carcinoma. Tumor Biol 2016;37:9301-10. [DOI: 10.1007/s13277-016-4794-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
124 Sun DW, An L, Wei F, Mu L, Shi XJ, Wang CL, Zhao ZW, Li TF, Lv GY. Prognostic significance of parameters from pretreatment (18)F-FDG PET in hepatocellular carcinoma: a meta-analysis. Abdom Radiol (NY) 2016;41:33-41. [PMID: 26830609 DOI: 10.1007/s00261-015-0603-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
125 Sun XD, Shi XJ, Chen YG, Wang CL, Ma Q, Lv GY. Elevated Preoperative Neutrophil-Lymphocyte Ratio Is Associated with Poor Prognosis in Hepatocellular Carcinoma Patients Treated with Liver Transplantation: A Meta-Analysis. Gastroenterol Res Pract. 2016;2016:4743808. [PMID: 26843858 DOI: 10.1155/2016/4743808] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
126 Shriki JE, Seyal AR, Dighe MK, Yeh MM, Jalikis FG, Andeen NK, Lall C, Bhargava P. CT of Atypical and Uncommon Presentations of Hepatocellular Carcinoma. AJR Am J Roentgenol 2015;205:W411-23. [PMID: 26397348 DOI: 10.2214/AJR.14.14000] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
127 Nath A, Li I, Roberts LR, Chan C. Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. Sci Rep. 2015;5:14752. [PMID: 26424075 DOI: 10.1038/srep14752] [Cited by in Crossref: 139] [Cited by in F6Publishing: 172] [Article Influence: 19.9] [Reference Citation Analysis]
128 Zhang W, Wang X, Jiang R, Hou J, Mu X, Li G, Sun B. Effect of Tumor Size on Cancer-Specific Survival in Small Hepatocellular Carcinoma. Mayo Clin Proc 2015;90:1187-95. [PMID: 26231292 DOI: 10.1016/j.mayocp.2015.06.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
129 Li H, Huang W, Luo R. The microRNA-325 inhibits hepatocellular carcinoma progression by targeting high mobility group box 1. Diagn Pathol 2015;10:117. [PMID: 26194496 DOI: 10.1186/s13000-015-0323-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
130 Liu CY, Chen KF, Chen PJ. Treatment of Liver Cancer. Cold Spring Harb Perspect Med 2015;5:a021535. [PMID: 26187874 DOI: 10.1101/cshperspect.a021535] [Cited by in Crossref: 85] [Cited by in F6Publishing: 130] [Article Influence: 12.1] [Reference Citation Analysis]
131 Chiu CC, Wang JJ, Chen YS, Chen JJ, Tsai TC, Lai CC, Sun DP, Shi HY. Trends and predictors of outcomes after surgery for hepatocellular carcinoma: A nationwide population-based study in Taiwan. Eur J Surg Oncol 2015;41:1170-8. [PMID: 26048295 DOI: 10.1016/j.ejso.2015.04.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
132 Li F, Liu T, Xiao CY, Yu JX, Lu LG, Xu MY. FOXP1 and SPINK1 reflect the risk of cirrhosis progression to HCC with HBV infection. Biomed Pharmacother 2015;72:103-8. [PMID: 26054682 DOI: 10.1016/j.biopha.2015.04.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
133 Gu HR, Park SC, Choi SJ, Lee JC, Kim YC, Han CJ, Kim J, Yang KY, Kim YJ, Noh GY, No SH, Jeong JH. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells. Clin Mol Hepatol 2015;21:49-59. [PMID: 25834802 DOI: 10.3350/cmh.2015.21.1.49] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
134 Gunasekaran SS, Emmadi R, Landers LA, Gaba RC. Regression of Hepatocellular Carcinoma Lung Metastases after Guyabano Fruit Extract Consumption. Journal of Dietary Supplements 2015;13:237-44. [DOI: 10.3109/19390211.2015.1008613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
135 Catalano O, Izzo F, Vallone P, Sandomenico F, Albino V, Nunziata A, Fusco R, Petrillo A. Integrating contrast-enhanced sonography in the follow-up algorithm of hepatocellular carcinoma treated with radiofrequency ablation: single cancer center experience. Acta Radiol 2015;56:133-42. [PMID: 24523360 DOI: 10.1177/0284185114521108] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
136 Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 2015;61:191-9. [PMID: 25142309 DOI: 10.1002/hep.27388] [Cited by in Crossref: 343] [Cited by in F6Publishing: 338] [Article Influence: 49.0] [Reference Citation Analysis]
137 Meier A, Yopp A, Mok H, Kandunoori P, Tiro J, Singal AG. Role functioning is associated with survival in patients with hepatocellular carcinoma. Qual Life Res 2015;24:1669-75. [PMID: 25502092 DOI: 10.1007/s11136-014-0895-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
138 Chen L, Zhang L, Liang M, Bao J, Zhang J, Xia Y, Huang X, Wang J. Magnetic resonance imaging with gadoxetic acid disodium for the detection of hepatocellular carcinoma: a meta-analysis of 18 studies. Acad Radiol 2014;21:1603-13. [PMID: 25262955 DOI: 10.1016/j.acra.2014.08.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
139 Tanase AM, Dumitrascu T, Dima S, Grigorie R, Marchio A, Pineau P, Popescu I. Influence of hepatitis viruses on clinicopathological profiles and long-term outcome in patients undergoing surgery for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2014;13:162-72. [PMID: 24686543 DOI: 10.1016/s1499-3872(14)60026-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
140 Chen J, Liu J, Jin R, Shen J, Liang Y, Ma R, Lin H, Liang X, Yu H, Cai X. Cytoplasmic and/or nuclear expression of β-catenin correlate with poor prognosis and unfavorable clinicopathological factors in hepatocellular carcinoma: a meta-analysis. PLoS One. 2014;9:e111885. [PMID: 25401330 DOI: 10.1371/journal.pone.0111885] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
141 Borzio M, Dionigi E, Rossini A, Toldi A, Francica G, Fornari F, Salmi A, Farinati F, Vicari S, Marignani M. Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an italian in-field experience. Dig Dis Sci. 2015;60:1465-1473. [PMID: 25399329 DOI: 10.1007/s10620-014-3427-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
142 Spolverato G, Kim Y, Alexandrescu S, Popescu I, Marques HP, Aldrighetti L, Clark Gamblin T, Miura J, Maithel SK, Squires MH, Pulitano C, Sandroussi C, Mentha G, Bauer TW, Newhook T, Shen F, Poultsides GA, Wallis Marsh J, Pawlik TM. Is Hepatic Resection for Large or Multifocal Intrahepatic Cholangiocarcinoma Justified? Results from a Multi-Institutional Collaboration. Ann Surg Oncol 2015;22:2218-25. [PMID: 25354576 DOI: 10.1245/s10434-014-4223-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 60] [Article Influence: 5.9] [Reference Citation Analysis]
143 Kulik LM, Chokechanachaisakul A. Evaluation and management of hepatocellular carcinoma. Clin Liver Dis. 2015;19:23-43. [PMID: 25454295 DOI: 10.1016/j.cld.2014.09.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
144 Singal AG, Marrero JA, Yopp A. Screening process failures for hepatocellular carcinoma. J Natl Compr Canc Netw 2014;12:375-82. [PMID: 24616543 DOI: 10.6004/jnccn.2014.0039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
145 Yang SL, Fang X, Huang ZZ, Liu XJ, Xiong ZF, Liu P, Yao HY, Li CH. Can serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma? A meta-analysis of the literature. Dis Markers. 2014;2014:127831. [PMID: 25378766 DOI: 10.1155/2014/127831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
146 Amini N, Ejaz A, Spolverato G, Maithel SK, Kim Y, Pawlik TM. Management of Lymph Nodes During Resection of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Systematic Review. J Gastrointest Surg 2014;18:2136-48. [DOI: 10.1007/s11605-014-2667-1] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 7.0] [Reference Citation Analysis]
147 Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol. 2014;28:843-853. [PMID: 25260312 DOI: 10.1016/j.bpg.2014.07.018] [Cited by in Crossref: 59] [Cited by in F6Publishing: 66] [Article Influence: 7.4] [Reference Citation Analysis]
148 Liu Y, Lu L, Jin H, Chen X, Zhang Z, Liu Z, Liang C. Radiofrequency ablation of liver VX2 tumor: experimental results with MR diffusion-weighted imaging at 3.0T. PLoS One. 2014;9:e104239. [PMID: 25102074 DOI: 10.1371/journal.pone.0104239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
149 Joshi K, Mendler M, Gish R, Loomba R, Kuo A, Patton H, Kono Y. Hepatocellular carcinoma surveillance: a national survey of current practices in the USA. Dig Dis Sci 2014;59:3073-7. [PMID: 25027206 DOI: 10.1007/s10620-014-3256-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
150 Kim DY, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012;1:2-14. [PMID: 24159567 DOI: 10.1159/000339016] [Cited by in Crossref: 73] [Cited by in F6Publishing: 85] [Article Influence: 9.1] [Reference Citation Analysis]
151 Gelu-Simeon M, Sobesky R, Haïm-Boukobza S, Ostos M, Teicher E, Fontaine H, Salmon-Ceron D, Meyer L, Trinchet JC, Paule B, Samuel D, Lewin M, Duclos-Vallée JC. Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIV-infected patients justify specific screening policies? AIDS 2014;28:1379-91. [PMID: 24785953 DOI: 10.1097/QAD.0000000000000300] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
152 Kim Y, Ejaz A, Tayal A, Spolverato G, Bridges JF, Anders RA, Pawlik TM. Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer 2014;120:3058-65. [PMID: 24917245 DOI: 10.1002/cncr.28843] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
153 Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review: Review of International HCC Guidelines. Cancer 2014;120:2824-38. [DOI: 10.1002/cncr.28730] [Cited by in Crossref: 153] [Cited by in F6Publishing: 172] [Article Influence: 19.1] [Reference Citation Analysis]
154 Cucchetti A, Trevisani F, Pecorelli A, Erroi V, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Giannini EG, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Baroni GS, Virdone R, Bernardi M, Pinna AD; Italian Liver Cancer Group. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. J Hepatol 2014;61:333-41. [PMID: 24717522 DOI: 10.1016/j.jhep.2014.03.037] [Cited by in Crossref: 70] [Cited by in F6Publishing: 76] [Article Influence: 8.8] [Reference Citation Analysis]
155 Devaki P, Wong RJ, Marupakula V, Nangia S, Nguyen L, Ditah IC, Ehrinpreis MN, Nguyen MH. Approximately one-half of patients with early-stage hepatocellular carcinoma meeting Milan criteria did not receive local tumor destructive or curative surgery in the post-MELD exception era. Cancer 2014;120:1725-32. [PMID: 24590359 DOI: 10.1002/cncr.28639] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
156 Ho EY, Cozen ML, Shen H, Lerrigo R, Trimble E, Ryan JC, Corvera CU, Monto A; HOVAS Group (Hepatocellular Carcinoma Treatment Outcome at VA San Francisco). Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma. HPB (Oxford). 2014;16:758-767. [PMID: 24467780 DOI: 10.1111/hpb.12214] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
157 Piñero F, Campaña AG, Mendizabal M, Fauda M, Rowe C, Raffa P, Barreiro M, Mahuad D, Testa P, Arufe D, Andriani O, Silva M, Podestá LG. Domino liver graft with hepatocellular carcinoma used as bridge therapy for a patient with acute liver failure: A case report: Letter from the Frontline. Liver Transpl 2014;20:386-7. [DOI: 10.1002/lt.23792] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
158 Thompson SM, Callstrom MR, Knudsen BE, Anderson JL, Sutor SL, Butters KA, Kuo C, Grande JP, Roberts LR, Woodrum DA. Molecular bioluminescence imaging as a noninvasive tool for monitoring tumor growth and therapeutic response to MRI-guided laser ablation in a rat model of hepatocellular carcinoma. Invest Radiol 2013;48:413-21. [PMID: 23262791 DOI: 10.1097/RLI.0b013e31827a4a3f] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
159 Salgia R, Singal AG. Hepatocellular Carcinoma and Other Liver Lesions. Medical Clinics of North America 2014;98:103-18. [DOI: 10.1016/j.mcna.2013.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
160 Shen P, Si J, Li QW, Qu LL, Li LR, Yan XL, Ji GZ. Human des-γ-carboxy prothrombin: Cloning, expression and monoclonal antibody preparation. Shijie Huaren Xiaohua Zazhi 2013; 21(35): 3932-3939 [DOI: 10.11569/wcjd.v21.i35.3932] [Reference Citation Analysis]
161 Vandecaveye V, Michielsen K, De Keyzer F, Laleman W, Komuta M, Op de beeck K, Roskams T, Nevens F, Verslype C, Maleux G. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome. Radiology 2014;270:747-57. [PMID: 24475816 DOI: 10.1148/radiol.13130591] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
162 Yip B, Wantuck JM, Kim LH, Wong RJ, Ahmed A, Garcia G, Nguyen MH. Clinical presentation and survival of Asian and non-Asian patients with HCV-related hepatocellular carcinoma. Dig Dis Sci 2014;59:192-200. [PMID: 24282055 DOI: 10.1007/s10620-013-2948-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
163 Solinas A, Chessa M, Culeddu N, Porcu MC, Virgilio G, Arcadu F, Deplano A, Cossu S, Scanu D, Migaleddu V. High resolution-magic angle spinning (HR-MAS) NMR-based metabolomic fingerprinting of early and recurrent hepatocellular carcinoma. Metabolomics 2014;10:616-26. [DOI: 10.1007/s11306-013-0601-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
164 Kudo M. Japan's Successful Model of Nationwide Hepatocellular Carcinoma Surveillance Highlighting the Urgent Need for Global Surveillance. Liver Cancer 2012;1:141-3. [PMID: 24159578 DOI: 10.1159/000342749] [Cited by in Crossref: 26] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
165 Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013;29:285-292. [PMID: 23507917 DOI: 10.1097/mog.0b013e32835ff1cf] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 7.8] [Reference Citation Analysis]
166 Lee JM, Yang J, Newell P, Singh S, Parwani A, Friedman SL, Nejak-Bowen KN, Monga SP. β-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation. Cancer Lett 2014;343:90-7. [PMID: 24071572 DOI: 10.1016/j.canlet.2013.09.020] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
167 Tan D, Yopp A, Beg MS, Gopal P, Singal AG. Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol Ther 2013;38:703-12. [PMID: 23957569 DOI: 10.1111/apt.12450] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 7.8] [Reference Citation Analysis]
168 Wang WW, Ang SF, Kumar R, Heah C, Utama A, Tania NP, Li H, Tan SH, Poo D, Choo SP, Chow WC, Tan CK, Toh HC. Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma. PLoS One 2013;8:e68904. [PMID: 23874805 DOI: 10.1371/journal.pone.0068904] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
169 Abdel-Rahman O, Abdel-Wahab M, Shaker M, Abdel-Wahab S, Elbassiony M, Ellithy M. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol 2013;30:655. [PMID: 23824645 DOI: 10.1007/s12032-013-0655-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
170 Niu Y, Huang T, Lian F, Li F. Contrast-enhanced ultrasonography for the diagnosis of small hepatocellular carcinoma: a meta-analysis and meta-regression analysis. Tumor Biol 2013;34:3667-74. [DOI: 10.1007/s13277-013-0948-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
171 Purysko AS, Remer EM, Coppa CP, Leão Filho HM, Thupili CR, Veniero JC. LI-RADS: a case-based review of the new categorization of liver findings in patients with end-stage liver disease. Radiographics 2012;32:1977-95. [PMID: 23150853 DOI: 10.1148/rg.327125026] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 7.4] [Reference Citation Analysis]
172 Izzo F, Piccirillo M, Albino V, Palaia R, Belli A, Granata V, Setola S, Fusco R, Petrillo A, Orlando R, Tosone G, Scordino F, Curley SA. Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients. HPB (Oxford) 2013;15:985-90. [PMID: 23607636 DOI: 10.1111/hpb.12080] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
173 Marshall A, Lukk M, Kutter C, Davies S, Alexander G, Odom DT. Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker. PLoS One. 2013;8:e59459. [PMID: 23527199 DOI: 10.1371/journal.pone.0059459] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
174 Chen P, Kao W, Chiou Y, Hung H, Su C, Chou Y, Huo T, Huang Y, Wu W, Chao Y, Lin H, Wu J. Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation. Annals of Hepatology 2013;12:263-73. [DOI: 10.1016/s1665-2681(19)31365-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
175 Groeschl RT, Clark Gamblin T, Turaga KK. Surgical resection in hepatocellular carcinoma patients with minimal background fibrosis: a strategy in the era of organ shortage. Ann Surg Oncol 2013;20:2043-8. [PMID: 23334253 DOI: 10.1245/s10434-012-2857-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
176 Wu W, Chen Y, Hwang C, Su C, Li S, Chen T, Liu C, Kao W, Chao Y, Lin H, Wu J. Second primary cancers in patients with hepatocellular carcinoma: a nationwide cohort study in Taiwan. Liver Int 2013;33:616-23. [DOI: 10.1111/liv.12103] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
177 Wong LL, Hernandez BY, Albright CL. Socioeconomic factors affect disparities in access to liver transplant for hepatocellular cancer. J Transplant 2012;2012:870659. [PMID: 23304446 DOI: 10.1155/2012/870659] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
178 Della Corte C, Colombo M. Surveillance for hepatocellular carcinoma. Semin Oncol. 2012;39:384-398. [PMID: 22846857 DOI: 10.1053/j.seminoncol.2012.05.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
179 Thompson KJ, Swan RZ, Iannitti DA, McKillop IH, Sindram D. Diet-induced obesity and ethanol impair progression of hepatocellular carcinoma in a mouse mesenteric vein injection model. Surg Endosc 2013;27:246-55. [PMID: 22806512 DOI: 10.1007/s00464-012-2429-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
180 Shebl FM, Capo-Ramos DE, Graubard BI, McGlynn KA, Altekruse SF. Socioeconomic status and hepatocellular carcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2012;21:1330-5. [PMID: 22669949 DOI: 10.1158/1055-9965.EPI-12-0124] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]